LAS VEGAS--(BUSINESS WIRE)--In a move that could spur huge opportunities for Neutra Corp. (OTCQB:NTRR) and others in the North American cannabis industry, Canada’s federal court significantly increased patients’ access to medicinal cannabis on Wednesday.
A federal court judge ruled that medical cannabis patients have the right to grow their own plants, reversing a ban instituted by Canada’s previous government. The ruling was the result of a group of British Columbia residents taking the nation to court in 2013, arguing that the law requiring cannabis patients to buy their medication from licensed producers instead of growing their own violated their Constitutional rights.
NTRR already has numerous relationships within the Canadian cannabis industry. Alongside its joint venture partner, Surface to Air Solutions (S2O2), NTRR is working to offer cannabis growers and other businesses a suite of horticultural technologies designed to reduce or eliminate reliance upon pesticides to produce healthy crops. The joint venture’s suite of products includes a plant stimulant, an antimicrobial hard-surface treatment and air scrubbers. Used together, the suite of products allows healthy plants to thrive without the use of pesticides and fungicides, which can be harmful if ingested. Some products are already in use by growers in the United States and Canada.
The ruling comes on the heels of new Prime Minister Justin Trudeau’s pledge to legalize adult-use cannabis across Canada, as well. Economists estimate that the country’s cannabis market could surpass USD $7 billion annually. To further capitalize on the projected growth of the Canadian cannabis industry, the company formed another joint venture last month with Vancouver-based Oceanview Health Services Ltd. to help research cutting-edge topical creams, oils, salves, lotions and other products that have been infused with medicinal cannabis. Oceanview is currently preparing to debut a new brand of cannabis-infused topical products, BeKind Topicals, in markets where cannabis is legal and regulated.
About Neutra Corp.
As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how they grow, what they grow, and how they consume cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, NTRR is constantly combing the industry for the latest and greatest to test, prove and bring to market.
By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA) and 22nd Century Group, Inc. (NASDAQ: XXII). For investing information and performance data, please visit www.neutrainc.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.